Blog Archive

Spotlight On – Q3 2023

RECENT FACET SUCCESSES – JUST A FEW HIGHLIGHTS FACET HELPS GOVERNMENT INVESTIGATE DEA DRUG OF CONCERN: Facet champions IND preparation and submission to study PK and safety of widely available supplement.  A large ex-US C...

Read More

Facet By The Numbers – Q2 2023

FACET BY THE NUMBERS Total submissions to FDA April – June 2023:  35 (on average almost 3 submissions a week!) Early-stage development highlights: preparation/submission of 3 new INDs and submitted over 22 IND amendments (e.g.,...

Read More

FDA Round Up – Q2 2023

FDA ROUNDUP: FDA issues important draft guidance for developers of psychedelic drugs for potential treatment of medical conditions (June 23, 2023).  Currently, there are hundreds of organizations across the world who are develo...

Read More

Did You Know – Q2 2023

DID YOU KNOW? Facet helps to develop products in every therapeutic area and has specialty expertise in ophthalmology, oncology, diagnostic/therapeutic radiopharmaceuticals, and controlled substances Facet’s scientific experts ...

Read More

Facet Life Sciences Team Focus – Q2 2023

Team FocusDr. Jason Mercer attended the annual Food and Drug Law Institute (FDLI) annual conference May 17-18 in Washington, DC.  The FDLI annual conference addresses complex legal, regulatory, compliance, and policy issues fac...

Read More
Go to Top